COA Press Release

A Strategic Alliance of AJMC

June 17, 2020
Coverage from the Community Oncology Alliance Virtual Meeting, held April 23-24, 2020.
April 25, 2020
Despite the immediate distraction from coronavirus disease 2019 (COVID-19), panelists at the 2020 Virtual Community Oncology Conference said community oncologists must keep pressure on pharmacy benefit managers (PBMs) as the 2020 campaign heats up—lest they lose the momentum to rein PBM practices within the umbrella of drug pricing reform.
April 25, 2020
The bright spot of telemedicine's success during the coronavirus disease 2019 pandemic cannot overshadow the stresses on patients and practices, which will both have ongoing challenges when the pandemic ends, said panelists during a legislative update on day 2 of the 2020 Virtual Community Oncology Conference, convened by the Community Oncology Alliance.
April 24, 2020
There's a way to boost participation in clinical trials and modernize the cumbersome process of patient accrual, noted current ASCO President Howard A. “Skip” Burris, MD, FACP, FASCO, on day 2 of Virtual COA 2020. It means shifting clinical trials out of hospitals and tertiary care centers and bringing them to the patients.
April 24, 2020
This week, the top managed care news included HHS' plans to allocate the remaining $70 billion in COVID-19 funding to providers; an analysis finding aggressive social distancing measures economically justified; highlights from this week's virtual Community Oncology Conference.
April 24, 2020
Oncology practices in 2-sided risk arrangements have reported mixed results, pointing to the need for more time to make the transition, said Michael Diaz, MD, president of Community Oncology Alliance.
April 23, 2020
Oncology practices could use more time to become accustomed to 2-sided risk even without a global pandemic, but the current crisis makes the need more urgent, say payment reform leaders at the Community Oncology Alliance virtual conference.
April 22, 2020
The American Journal of Managed Care® (AJMC®recently spoke with Dinesh Kapur, MD, of Eastern Connecticut Hematology and Oncology, also known as ECHO, an advanced community oncology conference. Kapur spoke about how the value of community oncology, clinicial trials, and how staff are spending remote work days developing artificial intelligence (AI) tools for predictive patient analytics to improve care.
April 21, 2020
In a preview interview for this year’s 2020 Community Oncology Conference, The American Journal of Managed Care® speaks with Anshu Jain, MD—radiation oncologist at Ashland Bellefonte Cancer Center in Ashland, Kentucky; assistant clinical professor at the Yale School of Medicine; and Community Oncology Alliance board member—on how important it is to always strive for excellence in medicine.
April 20, 2020
The American Journal of Managed Care® discussed integrating applied informatics into the oncology care setting with Debra Patt, MD, MPH, MBA, executive vice president of policy and strategy at Texas Oncology.
April 19, 2020
In the second part of a 2-part preview interview in advance of this year’s virtual 2020 Community Oncology Conference, The American Journal of Managed Care® speaks with Cheryl Larson, president and chief executive officer of the Midwest Business Group on Health, about how she is helping employer organizations navigate their pharmacy benefits managers and manage employee expectations. 
April 18, 2020
Individuals should register for Community Oncology Alliance's virtual meeting to hear "amazing" speakers present groundbreaking research, said Lalan Wilfong, MD, medical oncologist and vice president of value-based care and quality programs at Texas Oncology.
April 18, 2020
In the first part of a 2-part preview interview in advance of this year’s virtual 2020 Community Oncology Conference, The American Journal of Managed Care® speaks with Cheryl Larson, president and chief executive officer of the Midwest Business Group on Health, about how she is helping employer organizations navigate their pharmacy benefits managers and manage employee expectations. 
 
April 17, 2020
At this year's Community Oncology Conference, Antonio Ciaccia, the chief strategy officer of 3 Axis Advisors, will present about pharmacy benefit managers (PBMs) and drug pricing issues. The conference, hosted by the Community Oncology Alliance, takes place virtually on April 23 and April 24, and The American Journal of Managed Care® (AJMC®) is previewing some of the speakers and topics. 
 
April 17, 2020
The Community Oncology Alliance's annual conference is a space where industry experts and key opinion leaders can share ideas on improving patient care and advocate for community oncology, said Kathy Oubre, MS, chief operating officer at Pontchartrain Cancer Center.
April 17, 2020
This week, the top managed care news included a report that accountable care organizations may drop out of the Medicare Shared Savings Program; states and healthcare plans address unemployment brought on by COVID-19; a sneak peek of the virtual 2020 Community Oncology Conference.
April 15, 2020
Networking with other practices, sharing ideas, and getting physicians involved in the process can aid community practices moving to alternative payment models (APMs), said Michael Diaz, MD, president of Community Oncology Alliance.
 
April 14, 2020
The 2020 Community Oncology Conference, hosted by the Community Oncology Alliance (COA), takes place virtually on April 23 and April 24. The American Journal of Managed Care® (AJMC®) is bringing you a series of previews so you can learn more about what you'll hear when you attend this virtual meeting. In this interview we're speaking with Lee Schwartzberg, MD, FACP, the chief medical director of West Cancer Center and the chief medical officer of OneOncology, and who is moderating a stakeholder panel discussion on genomic profiling in cancer.
April 12, 2020
Patel, Kashyap. Dying Without Fear: The Pursuit of Eternity. Penguin Random House India; 2020.
April 11, 2020
“Quest for Value: Advancing Oncology Value-based Care,” this year’s first installment in the Institute for Value-Based Medicine (IVBM) from The American Journal of Managed Care®, zeroed in seniors, a population that’s growing not just in Florida but across the United States. Older Americans are more likely to develop cancer, but thanks to better detection and treatment, they are more likely to survive cancer, too.
April 10, 2020
The Community Oncology Alliance (COA) said it is worried that the safety of patients with cancer will be compromised if home infusion regulatory changes, brought about by the coronavirus disease 2019 (COVID-19) pandemic, expand; other groups support the changes, which affect Medicare patients using Part B drugs.
March 30, 2020
Part of the reason COA recommended a 'ramp up' period is we need time for the vendors to understand what they need to be incorporating in their software, said Michael Diaz, MD, president of Community Oncology Alliance.
March 20, 2020
Some patients with cancer are more vulnerable than others, said Jeffrey Patton, MD, acting chief executive officer and president of physician services of OneOncology, as well as chief executive office of Tennessee Oncology, which is down to its last 14-day supply of personal protective equipment.
March 19, 2020
“These are times of unprecedented and unimaginable challenges for our health care system."
March 19, 2020
"We want to make sure practices have time to learn, understand, adapt, and modify, to a new Oncology Care Model," said Michael Diaz, MD, president of Community Oncology Alliance.
March 03, 2020
Implementing alternative payment models in oncology is a complicated process. The models are not perfect, especially the Centers for Medicare and Medicaid Services’ Oncology Care Model (OCM), although several panelists saw improvements in the proposed successor model, Oncology Care First (OCF).
March 03, 2020
Payers have a crucial role in the future of community oncology, said Jeffery Patton, MD, of OneOncology, because it’s in their interest to help this lower-cost option thrive. 
February 26, 2020
While there are similarities to the Oncology Care Model, the new model has features “that could have a substantial impact on practices that choose to participate,” the authors write.
February 20, 2020
As today’s employers try to balance the need to provide healthcare for their workers while keeping an eye on cost, they are banding together to learn more about cancer care and how to gain value for the millions they are spending. Last fall during the Community Oncology Alliance Payer Exchange Summit, leaders from employer and purchasing groups shared experiences from their members in a roundtable discussion. 
January 31, 2020
Results come at the decision point for practices: Will it be 1-sided or 2-sided risk?
November 05, 2019
Oncology care groups have praised the multipayer Oncology Care Model (OCM) for transforming cancer care through greater focus on care navigation, palliative care, survivorship, and keeping patients out of the emergency department. But there are complaints that practices can be penalized for elements beyond their control—notably, the soaring cost of state-of-the-art immunotherapies that were not on the market when the OCM was conceived.
November 03, 2019
There has been much speculation among the 175 practices still taking part in the OCM what will happen when the 5-year model expires in 2021. The RFI document states that the Oncology Care First model would start in January 2021, “when no new episodes would be initiating in OCM.”  
November 01, 2019
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
October 30, 2019
Proposed changes to the Stark Law that would make collaboration easier have purposely excluded pharmaceutical manufacturers, according to speakers at the Community Oncology Alliance Payer Exchange Summit.
October 30, 2019
The Oncology Care Model is a leading innovation in the move from fee-for-service to value-based reimbursement in large part because CMS has made adjustments based on physician feedback, according to an agency official who addressed the Community Oncology Alliance Payer Exchange Summit.
October 29, 2019
What would a successor to the Oncology Care Model (OCM) look like? Community oncologists discuss at the Payer Exchange Summit sponsored by the Community Oncology Alliance.
October 29, 2019
Heading into 2019, the idea that oncology practices would fully embrace financial responsibility for clinical decisions still seemed far-fetched for many. And yet, when it was time to make the call, moving to 2-sided risk proved a “simple” decision, said Travis Brewer of Texas Oncology, who took part in a panel offering an update on the Oncology Care Model (OCM) at the start of the Community Oncology Alliance (COA) Payer Exchange Summit, which opened Monday in Tyson’s Corner, Virginia.
September 18, 2019
CMS made an “error of law” when it tried to expand a site-neutral payment system, a federal judge ruled.
September 17, 2019
The Community Oncology Alliance (COA) has submitted formal comments to CMS about the agency’s proposed Radiation Oncology Model. In the letter, COA noted that while they appreciate CMS' decision to issue a model that is focused on radiation oncology and to transition providers to value-based care, they also emphasized their opposition to mandatory demonstration projects and expressed concern that the proposed model will create unnecessary burdens and challenges to physicians.
 
August 09, 2019
Following CMS’ decision to make chimeric antigen receptor (CAR) T-cell therapy available to Medicare beneficiaries nationwide, including in the community oncology setting, the Community Oncology Alliance (COA) applauded the decision.
July 30, 2019
The Community Oncology Alliance (COA) is applauding the Trump administration for its Medicare payment rule updates for physicians and hospitals, saying that the updates demonstrate that HHS and CMS are serious about implementing major reforms to reduce physicians’ unnecessary paperwork and adding competition into the healthcare system.
July 24, 2019
On behalf of the Community Oncology Alliance (COA), Ted Okon, executive director of COA, has released a statement regarding the Prescription Drug Pricing Reduction Act.
July 11, 2019
In response to CMS’ announcement outlining the Radiation Oncology Alternative Payment Model, the Community Oncology Alliance (COA) has expressed concerns over the model being mandatory or “required” by the agency.
July 11, 2019
Community Oncology Alliance's (COA's) executive director Ted Okon has released a statement expressing disappointment over the Trump administration’s decision to abandon a proposed rule to eliminate rebates in Medicare Part D and Medicaid managed care.
June 16, 2019
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
June 14, 2019
This week, the top managed care news included the Community Oncology Alliance submitting an alternative to the Oncology Care Model; more study results demonstrating diabetes drugs can prevent renal failure; US task force recommending pre-exposure prophylaxis for HIV prevention.
June 12, 2019
The Community Oncology Alliance (COA) has filed its alternative to CMS' Oncology Care Model (OCM) with the Physician-Focused Payment Model Technical Advisory Committee.
June 12, 2019
Care coordination is crucial for mitigating challenges associated with aging and survivorship, explained Rose Gerber, director of patient advocacy and education for the Community Oncology Alliance.
June 04, 2019
Outlining a set of issues that need to be addressed under the Oncology Care Model (OCM), the Community Oncology Alliance (COA) is urging the Center for Medicare & Medicaid Innovation to delay the October 2019 deadline for practices to transition to 2-sided risk under the model.
May 30, 2019
Rose Gerber, director of patient advocacy and education for the Community Oncology Alliance, discusses how different structural barriers create access issues for patients looking to participate in clinical trials.
May 23, 2019
Through OneOncology, we will be able to identify best practices and support patients throughout the continuum of care, explained Jeff Patton, MD, chief executive officer of Tennessee Oncology.
May 21, 2019
While there are consequences of a 6-month episode of care under the Oncology Care Model (OCM), there will be trade-offs with any time window, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.
May 18, 2019
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, explains how partnerships like OneOncology can help community practices adapt to the rapidly changing cancer care and diagnostic landscape.
May 13, 2019
Rose Gerber, director of patient advocacy and education for the Community Oncology Alliance, discusses the importance of patient education in encouraging clinical trial participation, as well as the importance of trials being patient centered.
May 11, 2019
Clinical trials should be a part of the conversation early and throughout the cancer journey, explained Katie Goodman, RN, BSN, CCRP, director of clinical research, Florida Cancer Specialists & Research Institute.
May 09, 2019
Under the Oncology Care Model (OCM), there's a wide range of practice sizes, creating challenges for evaluation, said Basit Chaudhry, MD, PhD, founder of Tuple Health.
May 08, 2019
Jeff Patton, MD, chief executive officer of Tennessee Oncology, offers his reaction to CMS' proposal to ease restrictions on how Part D managed the 6 protected classes of drugs.
May 07, 2019
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, explains reimbursement challenges that community settings face with access to multigene testing.
May 02, 2019
In September 2018, Tennessee Oncology, New York Cancer and Blood Specialists, and West Cancer Center announced the launch of OneOncology. During the 2019 Community Oncology Conference, we sat down with Jeff Patton, MD, chief executive officer of Tennessee Oncology, and Robin Shah, chief development and marketing officer for OneOncology.
April 29, 2019
Basit Chaudhry, MD, PhD, founder of Tuple Health, explains why it's important to evaluate the adequacy of the novel therapy adjustment under the Oncology Care Model (OCM).
April 27, 2019
In addition to helping make treatment decisions, COTA's real-world data platform can help oncologists understand and identify areas where there is treatment variability and help them work to contain cost in the long run, explained C.K. Wang, MD, senior medical director, COTA.
April 25, 2019
Clinical trial criteria is really about patient safety and making sure participating patients don't experience undue risks, explained Katie Goodman, RN, BSN, CCRP, director of clinical research, Florida Cancer Specialists & Research Institute.
April 24, 2019
Early education and communication are needed for successful uptake of biosimilars, explained Sonia T. Oskouei, PharmD, director, Pharmacy Program Development for Biosimilars, Premier Inc. 
April 22, 2019
While the physician shortage is having an impact in rural areas, the impact of physician burnout is happening across the board, said Jeff Patton, MD, chief executive officer of Tennessee Oncology.
April 17, 2019
Conference coverage updates from the Community Oncology Alliance's annual meeting.
April 17, 2019
Part of the challenge has been the distribution of cost structure under the Oncology Care Model (OCM), particularly with respect to pharmaceuticals, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.
April 14, 2019
Real-world data offers a glimpse into what happens to patients treated by real-world doctors under real-world circumstances, explained C.K. Wang, MD, senior medical director, COTA.
April 12, 2019
The breast cancer community is very excited about the approval of atezolimuab for the treatment of triple-negative breast cancer, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
April 11, 2019
The guidances released by the FDA to expand inclusion criteria for cancer clinical trials is a step in the right direction, said Katie Goodman, RN, BSN, CCRP, director of clinical research, Florida Cancer Specialists & Research Institute.
April 11, 2019
Xarzio currently has the majority of the market share for filgrastim products, explained Sonia T. Oskouei, PharmD, director, Pharmacy Program Development for Biosimilars, Premier Inc.
April 09, 2019
Jeff Patton, MD, chief executive officer of Tennessee Oncology, discusses results from Oncology Care Model (OCM) performance period 3 (PP3) and challenges his practice still experiences with the model.
April 09, 2019
The Community Oncology Alliance (COA) is offering praise for the Senate Finance Committee over its pharmacy benefit manager (PBM) hearing, which COA called a reminder that PBMs refuse to acknowledge their role in rising drug costs.
April 07, 2019
Jeffrey A. Scott, MD, chief medical officer, Integra Connect, discusses how pharma can help community oncologists understand the value of novel and expensive therapies.
April 07, 2019
Results from performance period 3 (PP3) were somewhat concerning because the amount of practices that achieved a shared savings stayed stable from PP2, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.
April 06, 2019
C.K. Wang, MD, senior medical director, COTA, explains how COTA's real-world data platform can benefit payers.
April 06, 2019
As the technology improves, we’re going to see liquid biopsies used in multiple different cancers, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
April 05, 2019
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
April 05, 2019
Howard A. "Skip" Burris, III, MD, FACP, FASCO, president, clinical operations, and chief medical officer of Sarah Cannon Research Institute, discusses what's needed from a policy perspective to ensure access to next-generation sequencing (NGS) tests.
April 05, 2019
Patients won't participate in a clinical trial if it's too much of a burden, so we have to bring the trials to where the patients live, explained Katie Goodman, RN, BSN, CCRP, director of clinical research, Florida Cancer Specialists & Research Institute.
April 05, 2019
At the Community Oncology Alliance's 2019 Community Oncology Conference in Orlando, Florida, a panel discussed strategies for practices to collaborate and survive the recent wave of consolidation. Targeting employers is one solution.
April 05, 2019
The first day of the 2019 Community Oncology Conference, the major annual meeting of the Community Oncology Alliance (COA), featured an update on its effort to find alternatives to CMS' Oncology Care Model.
March 19, 2019
On day 1 of the Community Oncology Alliance (COA)'s annual Community Oncology Conference, held April 4-5 in Orlando, Florida, we spoke with Ted Okon, executive director of COA, and Sibel Blau, MD, medical director of Northwest Medical Specialties, PLLC.
March 15, 2019
The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy.
March 12, 2019
The federal government has been releasing a number of policies and proposals that will affect care delivery and are aimed at rising costs of care and prescription drugs.
February 08, 2019
The Community Oncology Alliance has released its 2018 Year in Review, offering a comprehensive look at highlights and successes from the year.
February 01, 2019
The Community Oncology Alliance (COA) applauded President Donald Trump, HHS Secretary Alex Azar, Inspector General Daniel Levinson, and HHS staff for staking a strong stance against rebates and proposing to overal the current system.
January 03, 2019
The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the Medicare Program International Pricing Index Model for Medicare Part B Drugs pre-poposed rule
November 27, 2018
Community Oncology Alliance (COA) responded to CMS' proposal to ease restrictions on how Medicare Part D and Medicare Advantage plans dictate access to 6 protected drug classes, calling the decision a potential nightmare for vulnerable patients with cancer.
November 05, 2018
The Community Oncology Alliance (COA) responded to CMS' final Physician Fee Schedule Rule by commending the agency for listening and responding to feedback from stakeholders.
November 01, 2018
To speak about the success and continued development of Priority Health's payment reform model in cancer care, John Fox, MD, medical director at Priority Health, joined Dennis Zoet, chief business development officer at Cancer and Hematology Centers of Western Michigan, on a panel at the Community Oncology Alliance Payer Exchange Summit.
October 31, 2018
I’ve seen one case recently where a patient received $172,000 of drugs that were totally wasted. So, we’re going to be looking at this, we’re going to be looking at these middlemen getting in the way of the patient and the physician making a decision about their therapy, explained Ted Okon, executive director of COA.
October 31, 2018
Looking at total cost of care is difficult and figuring out what the practice is responsible for and not responsible for can be very difficult to do, said Lalan Wilfong, MD, executive vice president of Quality Programs at Texas Oncology.
October 31, 2018
A patient has their own set of values, providers have their own set of values, and the people that pay for it have their own set of values. So, [we all need to] come together, explains Bo Gamble, Director Of Strategic Practice Initiatives at the Community Oncology Alliance.
October 31, 2018
At the Community Oncology Alliance Payer Exchange Summit, healthcare policy experts from a government relations firm and from the pharmaceutical industry provided an update on the progress with value-based agreements and also discussed the challenges posed by the existing infrastructure and operational framework.
October 30, 2018
I’m not quite certain that the system is equipped to provide a comfort level for clinicians that they’re ready to take on two-sided risk, explained Lyn Fitzgerald, senior vice president, US & Global Development at the National Comprehensive Cancer Network (NCCN).
October 30, 2018
We've noticed that all of these transformation activities– care transformation, quality improvement, are all actually working, explained Kavita Patel, MD, MS, non-resident senior fellow at the Brookings Institution.
October 30, 2018
"The cost of cancer care is rising dramatically," said Lalan Wilfong, MD, executive vice president of quality programs at Texas Oncology.
October 30, 2018
The Community Oncology Alliance (COA) has been working with its member practices and some payer partners who have successfully implemented innovative care delivery and payment models to develop a 2.0 version of CMS’ Oncology Care Model (OCM). A progress report was presented at COA’s Payer Exchange Summit held October 29-30 in Tyson’s Corner, Virginia.
October 30, 2018
While practice transformation is vital, community-based clinics continue to struggle with emergency department (ED) use, hospitalization, and risk stratification as they identify ways to reduce unnecessary expenditures within their Oncology Care Model (OCM) practice.
September 25, 2018
Community Oncology Alliance (COA) submitted formal comments to CMS in support of proposed changes to the 340B Drug Discount Program and site-neutral paymnts put forward in the Hospital Outpatient Prospective Payment (HOPPS) rule. However, they also submitted comments warning against proposals to introduce new third-party middlemen to the Part B system.
September 11, 2018
Community Oncology Alliance (COA) has submitted formal comments to CMS Administrator Seema Verma on the 2019 Medicare Physician Fee Schedule.
August 08, 2018
The Trump administration will allow Medicare Advantage plans to negotiate prices for Part B drugs by providing them the opportunity to create plans that utilize step therapy. However, some in the healthcare industry view step therapy, also known as "fail first," as dangerous to patients with life-threatening diseases, such as cancer.
July 30, 2018
The Community Oncology Alliance (COA) announced their support of CMS’ 2019 Outpatient Prospective Payment System (OPPS) Proposed Rule.
July 16, 2018
Following CMS’ announcement of proposed rules for the 2019 Medicare Physician Fee Schedule, Community Oncology Alliance (COA) released a statement calling the proposals “puzzling.” The statement details concern with 2 proposals.
July 09, 2018
The Community Oncology Alliance (COA) has voiced its support of the 340B Drug Discount Accountability Act, which would require hospitals to report their total 340B drug purchases and pay a small 0.1% user fee to the Health Resources and Services Administration.
July 05, 2018
The Community Oncology Alliance (COA) has filed a lawsuit in the US District Court for the District of Columbia, stating that the 2% sequester cut to Medicare Part B drug reimbursement is unconstitutional and illegal, and that it can harm patient care and have a huge impact on the communityc ancer care system.
May 28, 2018
Healthcare is experiencing something fundamentally different with nontraditional mergers across industries, explained Ted Okon, executive director of COA, at the 2018 Community Oncology Conference.
May 17, 2018
In a survey released by Community Oncology Alliance (COA), the majority of physicians reported concern over proposals to reform the Medicare Part B program
May 17, 2018
In response to President Donald Trump's blueprint on lowering drug prices and reducing out-of-pocket costs, Community Oncology Alliance (COA) commended the administration for working to put patients first and lower prices, while also urging caution for unintended consequences.
May 09, 2018
There are 3 legislative priorities for the Community Oncology Alliance (COA) that keep the focus on the patient and ensure better care, explained Ted Okon, executive director of COA, at the 2018 Community Oncology Conference.
April 20, 2018
Reimbursement models, novel gene therapy–based treatments, and price transparency: these were some of the topics covered by presenters and panelists at the annual meeting of the Community Oncology Alliance.
April 15, 2018
How are large employers adapting to, and benefiting from, the value-based care practices that are a payer demand and a provider imperative? This was the focus of a panel moderated by Bo Gamble, director of Strategic Practice Initiatives, Community Oncology Alliance (COA), during the 2018 Community Oncology Conference hosted by COA, April 12-13 in National Harbor, Maryland.
 
April 13, 2018
A panel of providers discussed key advocacy issues that affect patients and practices and could improve access to care and costs during the 2018 Community Oncology Conference, hosted by the Community Oncology Alliance, April 12-13 in National Harbor, Maryland.
April 13, 2018
Ray Page, DO, PhD, president and director of research at The Center for Cancer and Blood Disorders and chair-elect of the American Society of Clinical Oncology’s (ASCO) Clinical Practice Committee, provides a look at legislation to improve patient access to treatments and address drug pricing in cancer care.
April 13, 2018
There is currently a lack of transparency with pharmacy benefit managers around drug prices and where the rebates for drugs are going, but Congress is pushing for greater transparency that will benefit patients, said Ted Okon, executive director of the Community Oncology Alliance.
April 13, 2018
How are community practices coping with administering chimeric antigen receptor (CAR)-T treatments? At the 2018 Community Oncology Conference hosted by the Community Oncology Alliance, Houston Holmes, MD, MBA, FACP, Texas Oncology, shared his experience with administering CAR T-cells in a community cancer center–based setting.
April 12, 2018
The Merit-based Incentive Payment System (MIPS) is a big program designed to be applied to all clinicians, which makes it complex to figure out how to do right, explained Richard Kane, senior director at Avalere.
April 12, 2018
Typically, cancer pain management is carved out of policies that try to restrict opioid prescribing in an effort to combat the opioid epidemic, but with more and more patients surviving their cancer, there is some uncertainty regarding who is affected by these policies, explained Bob Twillman, PhD, executive director for the Academy of Integrative Pain Management.
April 12, 2018
Richard Kane and Caroline Pearson, both from Avalere Health, provided oncologists gathered at the 2018 Community Oncology Conference an overview of reimbursement programs offered by CMS and advice on navigating them.
April 12, 2018
At the 2018 Community Oncology Conference hosted by the Community Oncology Alliance, April 12-13 in National Harbor, Maryland, FDA Commissioner Scott Gottlieb, MD, provided the audience with an overview of current and future plans of the regulatory agency, particularly its strides within the molecular diagnostic testing space.
February 28, 2018
Coverage of patient-centered care from Patient-Centered Oncology Care, November 16-17, 2017. 
February 28, 2018
Coverage of patient-centered care updates from Patient-Centered Oncology Care, November 16-17, 2017. 
January 30, 2018
As a result of the Medicare Outpatient Prospective Payment System rule that took effect on January 1, 85% of 340B hospitals will see net payment increases in 2018. Rural hospitals will reap the largest benefits, according to an analysis conducted by Avalere and commissioned by Community Oncology Alliance.
 
December 15, 2017
"The Oncology Drug Marketplace: Trends in Discounting and Site of Care," commissioned by the Community Onoclogy Alliance and conducted by Berkley Research Group, found that 340B hospitals have a clear financial incentive to expand oncology services; 340B hospitals receive over one-third of all Part B oncology drug reimbursement; a disproportionate share of the shift in site of care is attributable to 340B hospitals; and between 2010 and 2015, statutory discounts and rebates paid by manufacturers have almost tripled and put upward pricing pressure on drugs.
October 25, 2017
Tuple Health, a healthcare technology startup, interviewed some of the stakeholders participating in value-based care delivery and OCM, to gain their perspective of the state of cancer care and healthcare reform. The results were presented at the Community Oncology Alliance Payer Exchange Summit on Oncology Payment Reform.
June 14, 2017
A rundown of sessions at The Community Oncology Alliance (COA) annual meeting, held April 27-28, 2017, near Washington DC. This year’s theme was Fueling the Cancer Moonshot.
April 28, 2017
Is rubber meeting the road with big data in cancer care? “No…rather, not yet,” Green said at the 2017 Community Oncology Conference, April 26-27, held at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.
April 27, 2017
At the 2017 Community Oncology Conference, participants discussed the impact of pharmacy benefit managers (PBMs) on oncology drug prices and patient access to much needed treatments.
February 17, 2017
An e-mail, from Mark Merritt, president and CEO of the trade group Pharmaceutical Care Management Association, to the organization’s board, lays out a plan to develop an aggressive campaign to convince the new administration that the fault rests with pharmaceutical manufacturers.
February 02, 2017
A white paper commissioned by the Community Oncology Alliance (COA) delved into the practice of “direct and indirect remuneration” fees administered by pharmacy benefit managers and how they could drive up drug prices for Medicare Part D beneficiaries and taxpayers.
December 19, 2016
At the Community Oncology Alliance (COA) Payer Exchange Summit V, 2 employer groups and a provider participated on a panel to provide practical insight into the extraordinary challenges and decisions that employers and employees with a cancer diagnosis are faced with.
December 15, 2016
At the Community Oncology Alliance (COA) Payer Exchange Summit V, panelists provided insights for successful implementation of payment models in oncology clinics.
December 15, 2016
Bruce Gould, MD, president and medical director, Northwest Georgia Oncology Center, and president of the Community Oncology Alliance, presented an overview of how cancer care has improved over the years and what the current challenges are.
November 23, 2016
At the 5th annual Patient-Centered Oncology Care® meeting in Baltimore, Maryland, moderator Bruce Feinberg, DO, was joined by a care provider, a payer, and a community oncology representative to discuss efforts that maintain the patient at the core of payment models.
November 01, 2016
CVS Health has reversed its decision on physician dispensing of specialty drugs, originally meant to be implemented by January 1, 2017.
October 26, 2016
At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance, oncologists and payers came together to discuss the role of collaboration and data sharing for the successful implementation of the Oncology Care Model.
October 26, 2016
At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance (COA), 2 employer groups and a provider participated on a panel to provide practical insight into the extraordinary challenges and decisions faced by employers and employees with a cancer diagnosis.
October 25, 2016
What are some of the challenges that clinical practices will face as they implement the Medicare Oncology Care Model (OCM)? What are some of the strategies that have worked for practices using similar payment models? These were some of the questions discussed at the Payer Exchange Summit V.
October 25, 2016
At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance, held October 24-25, 2016, in Tyson’s Corner, Virginia, Bruce Gould, MD, presented an overview of how cancer care has improved over the years, what the challenges are, and how practices can adapt to payment reform.
October 05, 2016
According to the 2016 Community Oncology Practice Impact Report, about 15 community practices in the United States have either closed or were acquired, each month since 2008.
August 31, 2016
A new report by the law firm Frier Levitt, commissioned by the Community Oncology Alliance, has found that restrictive tactics by pharmacy benefit managers, particularly in the specialty pharmacy arena, could restrict patient access to much needed medications.
June 21, 2016
At the annual meeting of The Community Oncology Alliance, oncologists sat through a crash course on biosimilars that was rendered by experts from the pharmaceutical industry.
June 21, 2016
Representatives from 3 clinics that successfully participated in the accreditation process for an Oncology Medical Home, participated on a panel at The Community Oncology Conference: Innovation in Cancer Care.
April 14, 2016
Representatives from 3 clinics that successfully participated in the Commission on Cancer accreditation process for the Oncology Medical Home model participated in a panel discussion on the first day of The Community Oncology Conference: Innovation in Cancer Care.
April 05, 2016
The study, commissioned by the Community Oncology Alliance, has found that overall costs for Medicare and commercial health plan enrollees have been increasing at the same rate as the cost of treating patients with cancer. This contradicts the popular notion that cancer care costs have far outpaced overall healthcare spending.
December 15, 2015
Providers and payers came together to discuss challenges and share success stories as they adapt to the changing healthcare realm.
October 30, 2015
The Community Oncology Alliance (COA) created its Payer Exchange Summit to get payers who are thinking about getting involved in oncology payment reform or want to know what to do exposed to successful pilots, explained Ted Okon, MBA, executive director of COA.
October 28, 2015
Payer—provider teams presented updates on their cost-saving pilot projects and looked to the future of these models in oncology care.
September 15, 2015
The American Journal of Managed Care spoke with Bruce J. Gould, MD, medical director of Northwest Georgia Oncology Centers on the impact of the 340B drug pricing program on private oncology practices.
July 07, 2015
The report found that Medicare Part B spending per beneficiary in 340B hospitals was more than twice that of hospitals outside the program. Groups such as the Community Oncology Alliance have long warned that the 340B program, while essential, has grown beyond its original intent.
April 24, 2015
The panel discussion, "Tackling Advanced Care Planning in Payment Reform: People and Politics" at the 2015 Community Oncology Conference, included a provider who is an active proponent of advanced care planning (ACP), a program director at a nonprofit health insurance company, and a healthcare consultant who until recently worked for a big health plan.
April 23, 2015
A general session at the Community Oncology Conference, Community Oncology 2.0, Moving Forward on Payment Reform, was a panel discussion that saw participation by 2 providers and a payer.
April 23, 2015
Given the high cost of oncology medications, many specialty pharmacies have dedicated teams to help patients overcome the financial burden, said Kirby Eng, RPh, executive director of clinical oncology management services at Onco360.
February 27, 2015
Ten oncology practices around the nation will initiate their accreditation process this year, which includes an on-site survey bu the Commission on Cancer.
January 27, 2015
One of the early findings from various oncology medical homes throughout the country was that they work, claimed Ted Okon, BS, MBA, executive director of the Coalition Oncology Alliance.
June 09, 2014
The continued advances in cancer treatment are improving patient survival, but the healthcare industry is bursting at its seams.
April 07, 2014
Highlights from recent AJMC conference coverage.
April 06, 2014
The session included insight from a panel of industry experts as they discussed the community oncology medical home model and payment reform.
April 06, 2014
Personalized medicines and targeted therapies are transforming the way cancer is treated. As these novel developments continue to evolve, so must the process of moving research findings into clinical practice, says Chris Beardmore, chief executive officer, Translational Research Management.
April 06, 2014
Four innovators from oncology practices across the country described how payment reform is shaping the way they treat cancer. While each of their experiences is unique, they all seemed to arrive at the same conclusion: one must find ways to adapt to the changing healthcare landscape.
April 04, 2014
When treating cancer in the new century, patients and their stories will come first, said Siddhartha Mukherjee, MD, DPhil. During a session analyzing the evolution of cancer detection and treatment, Dr Mukherjee said that stories animate cancer and help to personalize the patient's experience as they deal with treatment.
April 04, 2014
Utilizing an in-house pharmacy may present innovative and efficient opportunities for health providers seeking to improve patient engagement. In general, various trends are reshaping the role of the pharmacist in oncology practice, and the ways in which pharmacies function.
April 04, 2014
David Fryefield, MD, medical director for The US Oncology Network, says that 1 out of 5 times, cancer care delivery processes are defective. In fact, when considering processes that were value added, value enabling, or non-value added, about one-third of processes were non-value added. This can lead to inefficiency in cancer care delivery.
January 23, 2014
COA and ASCO are issuing a joint statement on payment reform in cancer care. The goal is to improve the lives of individuals with cancer, in part by developing and supporting payment systems based on evidence-based medicine and measures of quality and value in cancer care.
December 30, 2013
The coming year will be one for those who have beaten cancer to develop survivorship plans, with the Commission on Cancer to require planning by treatment centers starting in 2015.
January 02, 2013
In this video, Robert Bo Gamble, Director, Strategic Practice Initiatives, Community Oncology Alliance, Washington, DC, says that it is critical for payers and providers to come together in oncology management.
May 18, 2012
The oncology patient“centered medical home is a physician-driven, patient-focused value proposition that can make a difference for patients, oncologists, and the cost of healthcare.


Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.